Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1256 clinical trials
featured
TREATMENT OF LIVER FIBROSIS IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)

NASH IS LIVER INFLAMMATION AND DAMAGE CAUSED BY A BUILDUP OF FAT IN THE LIVER.  

  • 93 views
  • 03 Oct, 2019
  • 1 location
featured
A research study for patients with cystic fibrosis who might have a condition called Fibrosing Colonopathy (FC).

A research study for patients with cystic fibrosis who might have a condition called Fibrosing Colonopathy (FC).

  • 574 views
  • 07 Nov, 2020
  • 1 location
featured
NASH001 - Non-alcoholic Steatohepatitis (NASH) - CC-90001-NASH-001 - US  

and 400 mg PO QD), compared with placebo, in NASH subjects with Stage 3 and Stage 4 fibrosis.This study is designed to assess response to treatment on measures of fibrosis and other efficacy

  • 85 views
  • 05 Jan, 2021
  • 37 locations
featured
The AURORA Study

Assessing the efficacy and safety of Cenicriviroc for the treatment of liver fibrosis in adults with non-alcoholic steatohepatitis (NASH)  

  • 295 views
  • 23 Nov, 2020
  • 1 location
featured
NASH (Nonalcoholic Steatohepatitis)

Nonalcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver.  ClinSearch is enrolling volunteers with a condition called liver fibrosis from NASH

  • 35 views
  • 23 Nov, 2020
  • 1 location
featured
Clinical, Electrocardiographic, and Cardiac Magnetic Resonance Imaging Risk Factors Associated with Ventricular Tachyarrhythmias in Nonischemic Cardiomyopathy (MARVEN Study)

Implantable cardioverter defibrillator (ICD) for primary prevention of mortality is an approved therapy in ischemic and nonischemic cardiomyopathy patients with left ventricular ejection fraction (EF) ≤35%. However, data from clinical trials leading to this indication in nonischemic cardiomyopathy (NICM) patients were limited. The DEFINITE [1] trial (458 patients; hazard ratio …

heart study
  • 350 views
  • 24 Nov, 2020
  • 1 location
featured
Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

  • 2074 views
  • 08 Nov, 2020
  • 1 location
featured
Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that becomes worse over time. There is currently no effective treatment for it. Researchers

idiopathic pulmonary fibrosis
x-rays
chest x-ray
chest ct
walk tests
  • 162 views
  • 23 Nov, 2020
  • 1 location
featured
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

  • 210 views
  • 23 Nov, 2020
  • 1 location
featured
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 OR STAGE 4 LIVER FIBROSIS

The study aims to evaluate The effect of oral (PO) CC-90001, administered once daily (QD), compared with placebo, will be evaluated in subjects with NASH and Stage 3 fibrosis

  • 58 views
  • 23 Nov, 2020
  • 1 location